VK 5211

Drug Profile

VK 5211

Alternative Names: LGD 4033; VK-5211

Latest Information Update: 09 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Viking Therapeutics
  • Class Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hip fracture
  • Preclinical Cachexia
  • No development reported Hypogonadism; Muscular atrophy; Osteoporosis

Most Recent Events

  • 01 Oct 2018 Additional efficacy data from a phase II trial in Hip fracture released by Viking Therapeutics
  • 09 May 2018 VK 5211 is available for licensing as of 09 May 2018. http://www.vikingtherapeutics.com/
  • 01 Mar 2018 Viking Therapeutics completes a phase II trial in Hip fractures (In the elderly) in USA, Hungary, Romania and Serbia (NCT02578095)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top